Azacitidine for the treatment of progressive angioimmunoblastic T-cell lymphoma Prepared by the All Wales Therapeutics and Toxicology Centre Page 1 of 6 Azacitidine for the treatment of progressive angioimmunoblastic T-cell lymphoma (OW16) September 2023 ONE WALES INTERIM DECISION Azacitidine for the treatment of progressive angioimmunoblastic T-cell lymphoma Date of original advice : July 2020 Date of review: July 2023 The following One Wales Medicines Assessment Group (OWMAG) recommendation has been noted by the All Wales Medicines Strategy Group (AWMSG) and ratified by Welsh Government Using the agreed starting and stopping criteria, azacitidine can be made available within NHS Wales for the treatment of progressive angioimmunoblastic T-cell lymphoma. The risks and benefits
Venetoclax with azacitidine for treating acute myeloid leukaemia following allogeneic stem cell transplantation Venetoclax with azacitidine for treating acute myeloid leukaemia following allogeneic stem cell transplantation - NIHR Innovation Observatory * Who we are * What we do * Our Networks * Engage * Events * News * Resources Get in touch * * A world leading Horizon Scanning Facility The NIHR MedicinesMarch 2024 * Who we are * Meet the Team * Our Mission * Our Values * What we do * Emerging horizon * Transitional horizon * Imminent horizon * Our Networks * Our Stakeholders * Our Work with NICE * Health & Life Sciences Ecosystem * Engage * Industry * Public Involvement * Capacity Building * Events * News * Resources * Contact 29 May 2024 Venetoclax with azacitidine for treating acute myeloid
Ivosidenib (Tibsovo, Tidhesco ) in combination with azacitidine for the treatment of newly diagnosed acute myeloid leukaemia (AML) ENGLISH | DEUTSCH ATOM RSS 1.0 RSS 2.0SIMPLE SEARCHADVANCED SEARCHHELPSERVICESLOGINBrowseTypeSubjectAuthor / EditorInstitutionYear AIHTA - Publications - Search - Ivosidenib (Tibsovo®, Tidhesco® ) in combination with azacitidine for the treatment of newly diagnosed acute myeloid leukaemia (AML). Update April 2023Rothschedl, E. and Wolf, S. (2023): Ivosidenib (Tibsovo®, Tidhesco® ) in combination with azacitidine for the treatment of newly diagnosed acute myeloid leukaemia (AML). Update April 2023. Fact Sheet Nr. 126. PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader123kBItem Type: Horizon Scanning
Azacitidine oral (Onureg) - acute myeloid leukaemia 1 Published 10 July 2023 1 SMC2533 azacitidine film-coated tablets (Onureg®) Bristol Myers Squibb Pharmaceuticals Ltd 09 June 2023 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission assessed under the end of life and orphan equivalent medicine process azacitidine (Onureg®) is accepted for use within NHSScotland. Indication Under Review: maintenance therapy in adult patients with acute myeloid
Azacitidine (Onureg) - acute myeloid leukaemia (AML) PART VI: SUMMARY OF THE RISK MANAGEMENT PLAN 1. SUMMARY OF RISK MANAGEMENT PLAN FOR ONUREG (ORAL AZACITIDINE) This is a summary of the Risk Management Plan (RMP) for oral azacitidine (Onureg). The RMP details important risks of Onureg, how these risks can be minimised, and how more information will be obtained about Onureg’s risks therapy with or without consolidation treatment and who are not candidates for, including those who choose not to proceed to, haematopoietic stem cell transplantation (HSCT). See SmPC for the full indication. It contains azacitidine as the active substance and it is given by oral route of administration. Further information about the evaluation of Onureg’s benefits can be found in the EPAR for Onureg
Azacitidine for Acute myeloid leukemia Skip to main contentAboutCollaboration/OutreachPatient/CommunityCareersContactMy CADTHFRReportsResourcesProvide InputSubmit a RequestNews & EventsWhat Does The Evidence Say About...SearchBreadcrumbHome Azacitidine for Acute myeloid leukemiaCopied to clipboardAzacitidine for Acute myeloid leukemia( Last Updated : October 24, 2022)Project Status:CompletedProject Line:Health Technology ReviewProject Sub Line:Technology ReviewProject Number:HC0036-000Effective finish date:October 24, 2022DetailsThis custom health technology review will summarize evidence on the efficacy and safety of Azacitidine (intravenous and subcutaneous) as maintenance therapy for patients with Acute Myeloid Leukemia. FilesAzacitidine for Acute myeloid leukemiaRelated ContentIn Brief
Azacitidine (Onureg) for the maintenance treatment of patients with acute myeloid leukaemia (AML). Azacitidine (Onureg®) for the maintenance treatment of patients with acute myeloid leukaemia (AML). Update August 2021 - Repository of AIHTA GmbH English | Deutsch Atom RSS 1.0 RSS 2.0 * Simple search * Advanced search * Help * Services * Login * Browse * Type * Subject * Author / Editor * Institution * YearAIHTA - Publications - Search - Azacitidine (Onureg®) for the maintenance treatment of patients with acute myeloid leukaemia (AML). Update August 2021 Wolf, S.(2021):Azacitidine (Onureg®) for the maintenance treatment of patients with acute myeloid leukaemia (AML). Update August 2021. Oncology Fact Sheet Nr. 47.Preview PDF- Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie
Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy Treatment results for patients with newly diagnosed FMS-like tyrosine kinase 3 (FLT3)-mutated (FLT3mut+) acute myeloid leukemia (AML) ineligible for intensive chemotherapy are disappointing. This multicenter, open-label, phase 3 trial randomized (2:1) untreated adults with FLT3mut+ AML ineligible for intensive induction chemotherapy to gilteritinib (120 mg/day orally) and azacitidine (GIL+AZA) or azacitidine (AZA) alone. The primary endpoint was overall survival (OS). At the interim analysis (26 August 2020), 123 patients were randomized (GIL+AZA, n=74; AZA, n=49). Subsequent AML therapy, including FLT3 inhibitors, was received by 20.3% (GIL+AZA) and 44.9
Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phase 1/2 trial. Olutasidenib is a potent, selective, oral, small molecule inhibitor of mutant IDH1 (mIDH1) which induced durable remissions in high-risk, relapsed/refractory (R/R) mIDH1 AML patients in a phase 1/2 trial . We present a pooled analysis from multiple cohorts of the phase 1/2 trial of patients with R/R AML who received combination olutasidenib and azacitidine therapy. Adult patients with mIDH1 AML received 150 mg olutasidenib twice daily plus standard-of-care azacitidine (OLU + AZA) and were evaluated for response and safety. Sixty-seven patients with R/R mIDH1 AML received combination OLU + AZA. Median
Influence of Cytogenetics on the Outcome of Patients With High-Risk Myelodysplastic Syndrome Including Deletion 5q Treated With Azacitidine With or Without Lenalidomide. In myelodysplastic syndromes (MDS), cytogenetic characteristics of the malignant bone marrow cells influence the clinical course. The aim of this study was to evaluate whether cytogenetics is useful to predict outcome and response in patients with del(5q) under azacitidine (AZA) ± lenalidomide (LEN) therapy. We therefore performed comprehensive cytogenetic analyses in MDS patients with del(5q) treated within the randomized phase II trial NMDSG10B. Seventy-two patients were enrolled in the study and 46 patients (64%) had sufficient cytogenetics at inclusion and response evaluation. Karyotyping was significantly more
Magrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study. Patients with TP53-mutated acute myeloid leukemia (AML) have an extremely poor prognosis, necessitating new treatments. The global, randomized, phase 3 ENHANCE-2 trial evaluated the anti-CD47 monoclonal antibody magrolimab plus azacitidine (Magro/Aza) for previously untreated TP53-mutated AML. Patients determined inappropriate for intensive therapy were randomized to receive Magro/Aza or venetoclax plus azacitidine (Ven/Aza); those appropriate for intensive therapy were randomized to receive Magro/Aza or 7+3 induction chemotherapy. Primary endpoint was overall survival (OS) in the non-intensive arm. At interim analysis, non-intensive-arm OS hazard ratio (HR) between
Antileishmanial potentials of azacitidine and along with meglumine antimoniate on Leishmania major: In silico prediction and in vitro analysis. This study aimed to investigate the in vitro and in silico antileishmanial activity of azacitidine (AZA) on Leishmania major promastigotes and amastigotes. The in silico method was used to evaluate the possibility of the interaction of AZA
Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial Enasidenib is an oral inhibitor of mutant isocitrate dehydrogenase-2 (IDH2) proteins. We evaluated the safety and activity of enasidenib plus azacitidine versus azacitidine alone in patients with newly , and an Eastern Cooperative Oncology Group performance status of 0-2. In the phase 1b dose-finding portion, patients received oral enasidenib 100 mg/day or 200 mg/day in continuous 28-day cycles, plus subcutaneous azacitidine 75 mg/m per day for 7 days of each cycle. In phase 2, patients were randomly assigned (2:1) via an interactive web response system to enasidenib plus azacitidine or azacitidine-only